Khaled Musallam: Earlier Recognition, Better Outcomes in NTDT
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Advances, adding:
”Pleased to share another new Editorial out today in Blood Advances, a journal of the American Society of Hematology: ‘Too little, too late? The burden of delayed care in NTDT.’
A challenge that remains very real in non-transfusion-dependent thalassemia (NTDT) is delayed recognition, diagnosis, and referral to specialist care, with many patients reaching adulthood having already developed serious morbidities.
A reminder that NTDT is not a mild disease and that earlier recognition, specialist referral, and timely intervention can change its trajectory.”
Title: Too little, too late? The burden of delayed care in NTDT
Authors: Khaled M. Musallam, Thomas D. Coates, Ali T. Taher
Find more posts featuring Khaled Musallam on Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters